Literature DB >> 19071882

Ketolides--the modern relatives of macrolides : the pharmacokinetic perspective.

Markus Zeitlinger1, Claudia Christina Wagner, Birgit Heinisch.   

Abstract

As with other widely used antibacterials, the abundant use of macrolides for management of ambulant infections has promoted emergence of resistance against them. Ketolides are structurally related to macrolides and were developed to overcome macrolide resistance, while sharing pharmacodynamic and pharmacokinetic characteristics. However, until now, there have been no comprehensive reviews of the comparative pharmacokinetics of macrolides and ketolides. This article reviews the pharmacokinetic parameters in plasma and relevant tissues of telithromycin, the only approved ketolide, and cethromycin, which is currently in phase III of clinical development. For comparison, the 14-membered macrolides clarithromycin and roxithromycin and the 15-membered azalide azithromycin were chosen as representatives of their class. While telithromycin achieves higher plasma concentrations than cethromycin, both antimicrobials display comparable elimination half-lives and clearance. Repeated dosing rarely influences the pharmacokinetic parameters of ketolides. Despite substantially higher maximum plasma concentrations and area under the plasma concentration-time curve (AUC) values of telithromycin, the higher antimicrobial activity of cethromycin leads to similar ratios between the AUC from 0 to 24 hours (AUC(24)) and the minimum inhibitory concentration (MIC) for relevant pathogens, suggesting comparable antimicrobial activity of both antimicrobials in plasma. Although telithromycin and cethromycin show plasma-protein binding of 90%, they have excellent tissue penetration, as indicated by volumes of distribution of about 500 L and high intracellular concentrations. Besides enhancing killing of intracellular pathogens, the high concentrations of macrolides, azalides and ketolides in leukocytes have been associated with increased delivery of the antimicrobial agent to the site of infection. Although telithromycin has been shown to accumulate in alveolar macrophages and epithelial lining fluid by 380- and 15-fold, respectively (relative to plasma concentrations), its concentration in the interstitium of soft tissues is comparable to the free fraction in plasma. Thus the pharmacokinetics of ketolides may help to explain their good activity against a wide range of respiratory tract infections, although pharmacokinetic/pharmacodynamic calculations based on plasma pharmacokinetics would indicate only minor activity against pathogens except streptococci. In contrast, AUC(24)/MIC ratios achieved in soft tissue may be considered insufficient to kill extracellular pathogens causing soft tissue infections, except for Streptococcus pyogenes. Although ketolides and macrolides share relevant pharmacokinetic properties, the pharmacokinetics of both antimicrobial classes are not considered interchangeable. With a volume of distribution similar to that of azithromycin but plasma concentrations and an elimination half-life reflecting those of clarithromycin, the pharmacokinetics of ketolides may be considered 'intermediate' between those of macrolides and azalides. Thus the pharmacokinetics of ketolides can be considered similar but not identical to those of macrolides.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19071882     DOI: 10.2165/0003088-200948010-00002

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  179 in total

1.  Lung concentrations of telithromycin after oral dosing.

Authors:  O A Khair; J M Andrews; D Honeybourne; G Jevons; F Vacheron; R Wise
Journal:  J Antimicrob Chemother       Date:  2001-06       Impact factor: 5.790

2.  Microbiological efficacy of ABT-773 (cethromycin) for the treatment of community-acquired pneumonia due to Chlamydia pneumoniae.

Authors:  Margaret R Hammerschlag; Tamara Reznik; Patricia M Roblin; Julio Ramirez; James Summersgill; Stanley Bukofzer
Journal:  J Antimicrob Chemother       Date:  2003-02-25       Impact factor: 5.790

3.  Efficacy and safety of oral telithromycin once daily for 5 days versus moxifloxacin once daily for 10 days in the treatment of acute bacterial rhinosinusitis.

Authors:  Berrylin J Ferguson; Richard V Guzzetta; Sheldon L Spector; James A Hadley
Journal:  Otolaryngol Head Neck Surg       Date:  2004-09       Impact factor: 3.497

4.  Pharmacokinetics in serum and leukocyte exposures of oral azithromycin, 1,500 milligrams, given over a 3- or 5-day period in healthy subjects.

Authors:  G W Amsden; A N Nafziger; G Foulds
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191

5.  Activities of 16-membered ring macrolides and telithromycin against different genotypes of erythromycin-susceptible and erythromycin-resistant Streptococcus pyogenes and Streptococcus pneumoniae.

Authors:  Annarita Mazzariol; Raffaella Koncan; Luca Agostino Vitali; Giuseppe Cornaglia
Journal:  J Antimicrob Chemother       Date:  2007-04-03       Impact factor: 5.790

6.  Comparative studies of azithromycin in skin and soft-tissue infections and sexually transmitted infections by Neisseria and Chlamydia species.

Authors:  A Lassus
Journal:  J Antimicrob Chemother       Date:  1990-01       Impact factor: 5.790

7.  Ketolides lack inducibility properties of MLS(B) resistance phenotype.

Authors:  A Bonnefoy; A M Girard; C Agouridas; J F Chantot
Journal:  J Antimicrob Chemother       Date:  1997-07       Impact factor: 5.790

8.  Survival of Staphylococcus aureus inside neutrophils contributes to infection.

Authors:  H D Gresham; J H Lowrance; T E Caver; B S Wilson; A L Cheung; F P Lindberg
Journal:  J Immunol       Date:  2000-04-01       Impact factor: 5.422

9.  Streptococcus pneumoniae and Streptococcus pyogenes resistant to macrolides but sensitive to clindamycin: a common resistance pattern mediated by an efflux system.

Authors:  J Sutcliffe; A Tait-Kamradt; L Wondrack
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

10.  Efficacy and safety of telithromycin 800 mg once daily for 7 days in community-acquired pneumonia: an open-label, multicenter study.

Authors:  Charles M Fogarty; Tushar C Patel; Lala M Dunbar; Bruno P Leroy
Journal:  BMC Infect Dis       Date:  2005-05-31       Impact factor: 3.090

View more
  6 in total

1.  Blood, tissue, and intracellular concentrations of erythromycin and its metabolite anhydroerythromycin during and after therapy.

Authors:  S Krasniqi; P Matzneller; M Kinzig; F Sörgel; S Hüttner; E Lackner; M Müller; M Zeitlinger
Journal:  Antimicrob Agents Chemother       Date:  2011-11-14       Impact factor: 5.191

2.  Pharmacokinetics, safety, and biologic effects of azithromycin in extremely preterm infants at risk for ureaplasma colonization and bronchopulmonary dysplasia.

Authors:  Hazem E Hassan; Ahmed A Othman; Natalie D Eddington; Lynn Duffy; Li Xiao; Ken B Waites; David A Kaufman; Karen D Fairchild; Michael L Terrin; Rose M Viscardi
Journal:  J Clin Pharmacol       Date:  2010-11-23       Impact factor: 3.126

3.  Pharmacokinetics, microbial response, and pulmonary outcomes of multidose intravenous azithromycin in preterm infants at risk for Ureaplasma respiratory colonization.

Authors:  L Marcela Merchan; Hazem E Hassan; Michael L Terrin; Ken B Waites; David A Kaufman; Namasivayam Ambalavanan; Pamela Donohue; Susan J Dulkerian; Robert Schelonka; Laurence S Magder; Sagar Shukla; Natalie D Eddington; Rose M Viscardi
Journal:  Antimicrob Agents Chemother       Date:  2014-11-10       Impact factor: 5.191

4.  Azithromycin inhibits IL-1 secretion and non-canonical inflammasome activation.

Authors:  Guido A Gualdoni; Tilman Lingscheid; Klaus G Schmetterer; Annika Hennig; Peter Steinberger; Gerhard J Zlabinger
Journal:  Sci Rep       Date:  2015-07-08       Impact factor: 4.379

5.  Azithromycin suppresses CD4(+) T-cell activation by direct modulation of mTOR activity.

Authors:  F Ratzinger; H Haslacher; W Poeppl; G Hoermann; J J Kovarik; S Jutz; P Steinberger; H Burgmann; W F Pickl; K G Schmetterer
Journal:  Sci Rep       Date:  2014-12-11       Impact factor: 4.379

6.  Type III Secretion-Dependent Sensitivity of Escherichia coli O157 to Specific Ketolides.

Authors:  Romina J Fernandez-Brando; Nao Yamaguchi; Amin Tahoun; Sean P McAteer; Trudi Gillespie; Dai Wang; Sally A Argyle; Marina S Palermo; David L Gally
Journal:  Antimicrob Agents Chemother       Date:  2015-11-02       Impact factor: 5.191

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.